Clinical trials: TAS 102
Advanced or Metastatic Colorectal Cancer (mCRC)
Individual Patient Expanded Access to CA102N
This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.
- Trial name
- NCT05274204
- Testing
- CA102N
- Sponsor
- Holy Stone Healthcare Co., Ltd
Metastatic Colorectal Cancer
Lonsurf® (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in Taiwan
Primary Endpoint : To evaluate the Disease control rate (DCR) Secondary Endpoints: To evaluate the Progression-free survival (PFS), Overall survival(OS) and Safety profile
- Trial name
- NCT06495463
- Testing
- Trifluridine/tipiracil
- Where
- Taiwan
- Volunteers
- 97 people
- Sponsor
- Chang Gung Memorial Hospital
Metastatic Colorectal Cancer (CRC)
Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
This study is a randomized, controlled, open-label, phase II clinical study. This study is designed to evaluate the efficacy and safety of second-line standard treatment sequential TAS-102 and bevacizumab combined with local…
- Trial name
- TASBEL (NCT06856187)
- Testing
- TAS-102+bevacizumab+local treatment, Standard chemotherapy
- Where
- China
- Volunteers
- 119 people
- Sponsor
- Fudan University